Despite having a powerful discovery platform, Infinimmune deliberately avoided becoming a service company. The founders believed their unique ability to connect human antibody biology directly to potential assets gave them a competitive advantage in drug development that few other companies could replicate, making therapeutics the highest-impact path.

10x Genomics' leadership was highly disciplined, intentionally avoiding therapeutics to focus on life science tools. This strategic focus created a clear market gap that employees like Wyatt McDonnell could see. It presented an opportunity to leave, found Infinimmune, and become a customer of 10x to pursue that untapped potential.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

Xaira is building two parallel organizations: an AI product team and an R&D team. A key operational struggle is merging tech's rapid, months-long development cycles with biotech's methodical, decade-plus timelines. This cultural integration is a major hurdle for next-generation biopharma companies.

Beyond simple headcount growth, a biotech's culture must fundamentally shift as it matures. Moving into clinical trials requires a new focus on patient safety and regulation, while commercialization introduces intense pressure for compliance and revenue generation.

For a successful drug launch, biotech companies must abandon a sequential, siloed approach. The key is to start early, using an agile model where all functions (medical, commercial, regulatory) work in an integrated way from the outset. Rushing this complex process leads to costly mistakes.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Contrary to being a barrier, the pandemic forced a pause from intensive lab work, creating the mental space for the founding team to think strategically about commercializing their discoveries. The shift to virtual networking also democratized access to the Boston biotech ecosystem, accelerating the company's formation and early growth.

Moving from a science-focused research phase to building physical technology demonstrators is critical. The sooner a deep tech company does this, the faster it uncovers new real-world challenges, creates tangible proof for investors and customers, and fosters a culture of building, not just researching.